Medtronic Reports Strong Q1 2027 Performance with Strategic Growth Initiatives
Medtronic plc reported strong performance in the first quarter of fiscal year 2027, driven by organic revenue growth of 13.7%. This was fueled primarily by its 'Big 3' businesses: Cardiac Rhythm Management (CRM), Coronary Stents and Therapies (CST), and Surgical Technologies. The company's Cardiac Ablation Solutions saw an impressive 88% year-over-year revenue growth, supported by market share gains in the Sphere-9 platform and Affera mapping system reaching $2 billion in trailing twelve-month revenues. Management attributed this success to multi-year strategic changes aimed at improving commercial consistency. Operational efficiency programs are delivering cost savings through SKU rationalization and supply chain improvements. Medtronic also raised its full-year revenue guidance to 7.25%–7.75%, reflecting confidence in sustained growth trajectories across key segments. The company is strategically shifting toward high-growth areas such as neurovascular navigation and peripheral nerve stimulation, with a focus on robotics through the Hugo platform and new partnerships like Cornerstone Robotics.
